AVBP
NASD ArriVent BioPharma, Inc.$29.84 ↑ +0.30 (+1.02%) Trading Up from the previous close of $29.54
- YTD change
- +48.31%
- vs 20-day SMA
- +1.22%
- vs 200-day SMA
- +9.51%
Price ranges
Price & Performance
+8.53 (+40.60%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 18.0% away from all-time highs of $36.37
- AVBP is up 48% since the beginning of the year
- AVBP is up 62% over the past 12 months
- AVBP is down 1% over the past 1 month
- 27% of all AVBP investors are betting against AVBP
AVBP reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +60.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.04
- Last 5 days
- -1.58%
- vs 8-day SMA
- +0.87%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.